WEDNESDAY, 12th SEPTEMBER 2018 COMMENCING 09:30 AM
AT THE COPTHORNE HOTEL CARDIFF, COPTHORNE WAY,
CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

5. Chairman's report (verbal update)

6. Appraisal 1: Limited Submission
   Levonorgestrel (Kyleena®) for contraception for up to 5 years

7. Appraisal 2: Limited Submission
   Lanreotide (Somatuline® Autogel®) for the treatment of grade 1 and
   a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic
   neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or
   unknown origin where hindgut sites of origin have been excluded, in
   adult patients with unresectable locally advanced or metastatic
   disease

8. Appraisal 3: Limited Submission
   Octreotide (Sandostatin® LAR®) for the treatment of patients with
   advanced neuroendocrine tumours of the midgut or of unknown
   primary origin where non-midgut sites of origin have been excluded

   Data to March 2018

10. Feedback from All Wales Prescribing Advisory Group meeting held
    on 27th June 2018

Date of next meeting – Wednesday, 17th October 2018 in Cardiff

Enclosure

1/AWMSG/0918

2/AWMSG/0918

3/AWMSG/0918

4/AWMSG/0918

5/AWMSG/0918

6/AWMSG/0918

Appendices

Appendices

Appendices